Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospect...Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial.Methods: T2DM patients(n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar(FBS) level between 100-140 mg/dL received IND-2 capsules(700 mg, thrice a day) for 16 weeks.The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16.Secondary end-points include post-prandial blood sugar level, glycosylated Hb(HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks.Safety and adverse events(AEs) were also assessed during the study.Results: Study was completed in twenty T2DM patients, and there was no significant reduction in FBS and post-prandial blood sugar level after addon therapy of IND-2.However, add-on therapy of IND-2 significantly reduced(P<0.01) the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline.Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoproteincholesterol levels were significantly increased(P<0.01) after IND-2 add-on therapy.Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16.Additionally, add-on therapy of IND-2 did not produce any serious adverse events.Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia.Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.展开更多
The present study aimed at evaluation of prophylactic efficacy and possible mechanisms of asiaticoside （AS） based standardized extract of Centella asiatica （L.） Urban leaves （INDCA） in animal models of migraine....The present study aimed at evaluation of prophylactic efficacy and possible mechanisms of asiaticoside （AS） based standardized extract of Centella asiatica （L.） Urban leaves （INDCA） in animal models of migraine. The effects of oral and intranasal （i.n.） pretreatment of INDCA （acute and 7-days subacute） were evaluated against nitroglycerine （NTG, 10 mg·kg^-1, i.p.） and bradykinin （BK, 10 μg, intra-arterial） induced hyperalgesia in rats. Tail flick latencies （from 0 to 240 rain） post-NTG treatment and the number of vocalizations post-BK treatment were recorded as a measure of hyperalgesia. Separate groups of rats for negative （Normal） and positive （sumatriptan, 42 mg.kg ^-1, s.c.） controls were included. The interaction of 1NDCA with selective 5-HT1A, 5-HT1B, and 5-HTI D receptor antagonists （NAN-190, Isamoltane hemifumarate, and BRL-15572 respectively） against NTG-induced hyperalgesia was also evaluated. Acute and sub-acute pre-treatment of INDCA [10 and 30 mg.kg^-1 （oral） and 100 μg/rat （i.n.） showed significant anti-nociception activity, and reversal of the NTG-induced hypera｜gesia and brain 5-HT concentration decline. Oral pre-treatment with INDCA （30 mg·kg ^-1, 7 d） showed significant reduction in the number of vocalization. The anti-nociceptive effects of INDCA were blocked by 5-HTIA and 5-HT1B but not 5-HT1D receptor antagonists. In conclusion, 1NDCA demonstrated promising anti-nociceptive effects in animal models of migraine, probably through 5-HT1A/1B medicated action.展开更多
Purpose： To evaluate the efficacy and safety of the glycoside fraction of fenugreek （Trigonellafoenum-graecum） seeds （Fenu-FG） on physiologi- cal parameters related to muscle anabolism, androgenic hormones, and b...Purpose： To evaluate the efficacy and safety of the glycoside fraction of fenugreek （Trigonellafoenum-graecum） seeds （Fenu-FG） on physiologi- cal parameters related to muscle anabolism, androgenic hormones, and body fat in healthy male subjects during an 8-week resistance training program using a prospective, randomized, double-blind, placebo controlled design. Methods： Sixty healthy male subjects were randomized to ingest capsules of Fenu-FG （1 capsule of 300 rag, twice per day） or the matching placebo at a 1：1 ratio. The subjects participated in a supervised 4-day per week resistance-training program for 8 weeks. The outcome measurements were recorded at recruitment （baseline） and at the end of the treatment （8 weeks）. The efficacy outcome included serum testosterone （total and free） levels, muscle strength and repetitions to failure, metabolic markers for anabolic activity （serum creatinine and blood urea nitrogen）, and % body fat. The standard safety measurements such as adverse events monitoring, vital signs, hematology, biochemistry, and urinalysis were performed. Results： Fenu-FG supplementation demonstrated significant anabolic and androgenic activity as compared with the placebo. Fenu-FG treated subjects showed significant improvements in body fat without a reduction in muscle strength or repetitions to failure. The Fenu-FG supplemen- tation was found to be safe and well-tolerated. Conclusion： Fenu-FG supplementation showed beneficial effects in male subjects during resistance training without any clinical side effects.展开更多
文摘Objective: To assess the safety and efficacy of herbal formulation rich in standardized fenugreek seed extract(IND-2) add-on therapy in type 2 diabetes mellitus(T2DM) patients who were on insulin treatment in prospective, single arm, open-label, uncontrolled, multicentre trial.Methods: T2DM patients(n=30) with aged 18-80 years who were stabilized on insulin treatment with fasting blood sugar(FBS) level between 100-140 mg/dL received IND-2 capsules(700 mg, thrice a day) for 16 weeks.The primary endpoints were an assessment of FBS at week 2, 4, 6, 8, 12 and 16.Secondary end-points include post-prandial blood sugar level, glycosylated Hb(HbA1c), reduction in the dose of insulin and number of hypoglycemic attacks, and improvement in lipid profile at various weeks.Safety and adverse events(AEs) were also assessed during the study.Results: Study was completed in twenty T2DM patients, and there was no significant reduction in FBS and post-prandial blood sugar level after addon therapy of IND-2.However, add-on therapy of IND-2 significantly reduced(P<0.01) the HbA1c values, requirements of insulin and hypoglycemic events as compared with baseline.Total cholesterol, high-density lipoproteins-cholesterol, and low-density lipoproteincholesterol levels were significantly increased(P<0.01) after IND-2 add-on therapy.Body weight and safety outcomes did not differ significantly in IND-2 add-on therapy group at week 16.Additionally, add-on therapy of IND-2 did not produce any serious adverse events.Conclusions: The results of present investigation suggest that add-on therapy of IND-2 with insulin in T2DM patients improves glycaemic control through a decrease in levels of HbA1c and number of insulin doses needed per day without an increase in body weight and risk of hypoglycemia.Thus, IND-2 may provide a safe and well-tolerated add-on therapy option for the management of T2DM.
文摘The present study aimed at evaluation of prophylactic efficacy and possible mechanisms of asiaticoside （AS） based standardized extract of Centella asiatica （L.） Urban leaves （INDCA） in animal models of migraine. The effects of oral and intranasal （i.n.） pretreatment of INDCA （acute and 7-days subacute） were evaluated against nitroglycerine （NTG, 10 mg·kg^-1, i.p.） and bradykinin （BK, 10 μg, intra-arterial） induced hyperalgesia in rats. Tail flick latencies （from 0 to 240 rain） post-NTG treatment and the number of vocalizations post-BK treatment were recorded as a measure of hyperalgesia. Separate groups of rats for negative （Normal） and positive （sumatriptan, 42 mg.kg ^-1, s.c.） controls were included. The interaction of 1NDCA with selective 5-HT1A, 5-HT1B, and 5-HTI D receptor antagonists （NAN-190, Isamoltane hemifumarate, and BRL-15572 respectively） against NTG-induced hyperalgesia was also evaluated. Acute and sub-acute pre-treatment of INDCA [10 and 30 mg.kg^-1 （oral） and 100 μg/rat （i.n.） showed significant anti-nociception activity, and reversal of the NTG-induced hypera｜gesia and brain 5-HT concentration decline. Oral pre-treatment with INDCA （30 mg·kg ^-1, 7 d） showed significant reduction in the number of vocalization. The anti-nociceptive effects of INDCA were blocked by 5-HTIA and 5-HT1B but not 5-HT1D receptor antagonists. In conclusion, 1NDCA demonstrated promising anti-nociceptive effects in animal models of migraine, probably through 5-HT1A/1B medicated action.
基金supported by the Indus Biotech Private Ltd.,Pune with no role in the collection,analysis,and interpretation of data and the writing of the report
文摘Purpose： To evaluate the efficacy and safety of the glycoside fraction of fenugreek （Trigonellafoenum-graecum） seeds （Fenu-FG） on physiologi- cal parameters related to muscle anabolism, androgenic hormones, and body fat in healthy male subjects during an 8-week resistance training program using a prospective, randomized, double-blind, placebo controlled design. Methods： Sixty healthy male subjects were randomized to ingest capsules of Fenu-FG （1 capsule of 300 rag, twice per day） or the matching placebo at a 1：1 ratio. The subjects participated in a supervised 4-day per week resistance-training program for 8 weeks. The outcome measurements were recorded at recruitment （baseline） and at the end of the treatment （8 weeks）. The efficacy outcome included serum testosterone （total and free） levels, muscle strength and repetitions to failure, metabolic markers for anabolic activity （serum creatinine and blood urea nitrogen）, and % body fat. The standard safety measurements such as adverse events monitoring, vital signs, hematology, biochemistry, and urinalysis were performed. Results： Fenu-FG supplementation demonstrated significant anabolic and androgenic activity as compared with the placebo. Fenu-FG treated subjects showed significant improvements in body fat without a reduction in muscle strength or repetitions to failure. The Fenu-FG supplemen- tation was found to be safe and well-tolerated. Conclusion： Fenu-FG supplementation showed beneficial effects in male subjects during resistance training without any clinical side effects.
